Trastuzumab (Kanjinti) Stability

QCNW-Liverpool has recently completed a large study on the stability and continued potency of patient preparation of the Trastuzumab biosimilar Kanjinti, with the support of Amgen.

The study covered a range of concentrations (0.3mg/ml to 21mg/ml) and containers (IV bags and Intermate devices), with the final reports being supplied to NHS Pharmacies within the United Kingdom. It is intended to have the data published to allow wider access to the data within the healthcare community, however, in the meantime if you wish to have access to the generated reports please request this using the form within the ‘Contact’ section of the website.

Published: 12/10/2020 Published by: Quality Control North West Liverpool

Return to News Page.